Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Cancer

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2015.06.115PMID 26199039PMCID PMC5693226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strategies for the management of adverse events associated with mTOR inhibitors.

  2014cited by this paper
• Activation of the NOTCH pathway in head and neck cancer.

  2014cited by this paper
• A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors

  2013cited by this paper
• Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

  2013cited by this paper
• Mammalian target of rapamycin inhibitor-associated stomatitis.

  2013cited by this paper
• Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)

  2013cited by this paper
• PTEN deficiency contributes to the development and progression of head and neck cancer.

  2013cited by this paper
• Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

  2013cited by this paper
• A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

  2013cited by this paper
• A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

  2013cited by this paper
• Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial

  2012cited by this paper
• Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.

  2012cited by this paper
• Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.

  2012cited by this paper
• The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

  2011cited by this paper
• Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

  2011cited by this paper
• Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation

  2011cited by this paper
• Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

  2011cited by this paper
• Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.

  2011cited by this paper
• Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.

  2011cited by this paper
• Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.

  2011cited by this paper
• Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.

  2011cited by this paper
• Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

  2011cited by this paper
• Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

  2010cited by this paper
• Ridaforolimus

  2010cited by this paper
• Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.

  2010cited by this paper
• Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling.

  2010cited by this paper
• Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

  2008cited by this paper
• Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

  2008cited by this paper
• The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy

  2007cited by this paper
• Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.

  2006cited by this paper
• Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

  2006cited by this paper
• Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

  2005cited by this paper
• γ-Secretase: proteasome of the membrane?

  2004cited by this paper

• Key subunits of γ-secretase complex and breast cancer progression: biological function, regulation mode and therapeutic potential.

  2025cites this paper
• Molecular Mechanisms of Lymphatic Metastasis in Breast Cancer: An Updated Review

  2025cites this paper
• Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update

  2025cites this paper
• Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights

  2025cites this paper
• A novel platelets-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer

  2024cites this paper
• Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment

  2024cites this paper
• Notch signaling pathway in cancer: from mechanistic insights to targeted therapies

  2024cites this paper
• Notch‐Targeted Therapeutic in Colorectal Cancer by Notch1 Attenuation Via Tumor Microenvironment‐Responsive Cascade DNA Delivery

  2024cites this paper
• Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review

  2024cites this paper
• Structural basis of human γ-secretase inhibition by anticancer clinical compounds

  2024cites this paper
• Cancer stem cell in prostate cancer progression, metastasis and therapy resistance.

  2023cites this paper
• Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I

  2023cites this paper
• The Research Progress of Wnt/β-catenin Signaling Pathway in Colorectal Cancer.

  2023cites this paper
• Cancer stem cells as a therapeutic target: current clinical development and future prospective.

  2023cites this paper
• Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

  2023cites this paper
• Systematic analysis reveals distinct roles of USF family proteins in various cancer types

  2023cites this paper
• Update on immune‐based therapy strategies targeting cancer stem cells

  2023cites this paper
• Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment

  2023cites this paper
• In vitro antineoplastic effects of MK0752 in HPV-positive head and neck squamous cell carcinoma

  2023cites this paper
• DNA Damage Response Inhibition-Based Combination Therapies

  2023cites this paper
• Combination Therapy as a Promising Way to Fight Oral Cancer

  2023cites this paper
• The role of NF-κB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy.

  2023cites this paper
• Breast Cancer Metastasis: Mechanisms and Therapeutic Implications

  2022cites this paper
• AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling

  2022cites this paper
• Small molecules targeting γ-secretase and their potential biological applications.

  2022cites this paper
• Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo

  2021cites this paper
• Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo

  2021cites this paper
• Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer

  2021cites this paper
• Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions

  2021cites this paper
• Oral Cancer Stem Cells: Therapeutic Implications and Challenges

  2021cites this paper
• Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

  2021cites this paper
• Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells

  2021cites this paper
• Delta-Like Ligand–Notch1 Signaling Is Selectively Modulated by HPV16 E6 to Promote Squamous Cell Proliferation and Correlates with Cervical Cancer Prognosis

  2021cites this paper
• Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy

  2020cites this paper
• Pediatric hemispheric high-grade glioma: targeting the future

  2020cites this paper
• Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials

  2020cites this paper
• Function and mechanism exploration of zinc finger protein 64 in lung adenocarcinoma cell growth and metastasis

  2020cites this paper
• Tumor microenvironment pathways: Cross regulation in breast cancer metastasis

  2020cites this paper
• Systemic sterile induced-co-expression of IL-12 and IL-18 drives IFN-γ-dependent activation of microglia and recruitment of MHC-II-expressing inflammatory monocytes into the brain

  2020cites this paper
• Notch and breast cancer metastasis: Current knowledge, new sights and targeted therapy

  2019cites this paper
• Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update

  2019cites this paper
• Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights

  2019cites this paper
• Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer

  2019cites this paper
• Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?

  2018cites this paper
• Role of the NOTCH Signaling Pathway in Head and Neck Cancer

  2018cites this paper
• Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.

  2018cites this paper
• Notch and Breast Cancer Metastasis

  2018cites this paper
• Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.

  2018cites this paper
• Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS)

  2018cites this paper
• A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours

  2018cites this paper
• The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets

  2017cites this paper
• Relevance of chromosomal band 11q13 in oral carcinogenesis: An update of current knowledge.

  2017cites this paper
• Recent advances in targeting mTOR signaling pathway using small molecule inhibitors

  2017cites this paper
• A unified model of the hierarchical and stochastic theories of gastric cancer

  2017cites this paper
• Cancer stem cells: The root of tumor recurrence and metastases.

  2017cites this paper
• The γ-Secretase Protease Complexes in Neurodegeneration, Cancer and Immunity

  2017cites this paper
• The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets.

  2017cites this paper
• Caloric restriction - A promising anti-cancer approach: From molecular mechanisms to clinical trials.

  2017cites this paper
• Overview: Cancer Stem Cell Self-Renewal

  2017cites this paper
• Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment

  2017cites this paper
• New Opportunities and Challenges to Defeat Cancer Stem Cells.

  2017influential citation
• Exploring Novel Stratified Therapeutic Targets in B- Cell Chronic Lymphocytic Leukaemia

  2017cites this paper
• Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma

  2017cites this paper
• Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures

  2017cites this paper
• An update on the implications of cyclin D1 in oral carcinogenesis.

  2017cites this paper
• Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer.

  2016cites this paper
• Activation of multiple angiogenic signaling pathways in hemangiopericytoma

  2016cites this paper
• Autophagy Modulation for Organelle-Targeting Therapy

  2016cites this paper
• Genomically personalized therapy in head and neck cancer

  2016cites this paper
• Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases.

  2016cites this paper
• Investigational drugs for head and neck cancer

  2016cites this paper
• mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer

  2016cites this paper
• Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.

  2016cites this paper
• Activation of AKT negatively regulates the pro-apoptotic function of death-associated protein kinase 3 (DAPK3) in prostate cancer

  2016cites this paper
• Elevated autocrine chemokine ligand 18 expression promotes oral cancer cell growth and invasion via Akt activation

  2016cites this paper
• The therapeutic potential of mTOR inhibitors in breast cancer.

  2016cites this paper
• Title : An update on the implications of Cyclin D 1 in oral carcinogenesis . Running head : Cyclin D 1 in oral carcinogenesis

  2016cites this paper
• The PI3K Signaling Pathway in Head and Neck Squamous Cell Carcinoma

  2014cites this paper
• 2 3 Hey Factors at the Q1 Crossroad of Tumorigenesis 4 and Clinical Therapeutic Q2 Modulation of Hey for 5 Anticancer Q3 Treatment

  year unknowncites this paper